Phase II Open Label Multicenter Study of Early REinFusion of Tisagenlecleucel to Promote DUrable B-CEll ApLasia in Pediatric and Young Adult Patients With Relapsed/Refractory CD19-Positive B-Cell Acute Lymphoblastic Leukemia (REFUEL)
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms REFUEL
Most Recent Events
- 24 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2026.
- 16 Aug 2023 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2026.